Nanomedicine and Drug Delivery Laboratory: Uday B. Kompella, PhD
Research in the Kompella lab is currently focused on nanotechnology as it pertains to drug and gene delivery via ocular, nasal, and pulmonary routes of administration. The research group utilizes supercritical fluid technology for the preparation of polymeric nanoparticles, nanoporous particles, microparticles, and soluble complexes used as novel therapeutic agents for the treatment of diabetic retinopathy, age-related macular degeneration, corneal angiogenesis, and cancers.
Uday Kompella PhD, FARVO, FAAPS
Colorado Center for Nanomedicine and Nanosafety Co-Director and Co-founder
Professor of Pharmaceutical Sciences, Ophthalmology, and Bioengineering
Phone:303-724-4028
Dr. Kompella is a Professor of Pharmaceutical Sciences, Ophthalmology, and Bioengineering at University of Colorado, Anschutz Medical Campus, with research interests in the areas of drug discovery, drug delivery, and nanotechnology for treating a variety of degenerative, neovascular, and inflammatory disorders including retinitis pigmentosa, age-related macular degeneration (AMD), diabetic retinopathy, and cancers. Ocugen, Inc. is a public company co-founded by Dr. Kompella. Dr. Kompella is a Fellow of the American Association of Pharmaceutical Scientists (AAPS) and the Association for Research in Vision and Ophthalmology (ARVO) and serves as the Editor-in-Chief for the journals Expert Opinion on Drug Delivery and Journal of Ocular Pharmacology and Therapeutics. He served as an editor for the journal, Pharmaceutical Research, for sixteen years. Dr. Kompella is a recipient of the Distinguished Scientist Award (University of Nebraska Medical Center), Distinguished Teacher Award (University of Nebraska Medical Center), Dean’s Mentoring Award and Innovations in Science Award (University of Colorado Anschutz Medical Campus), and Undergraduate Alumni Teaching Excellence Award (Auburn University). He is also a recipient of the ARVO Foundation for Eye Research/Pfizer Ophthalmics/Carl Camras Translational Research Award in Ophthalmology. Dr. Kompella obtained his PhD in Pharmaceutical Sciences from the University of Southern California.
- Ocular, respiratory, and brain drug discovery, delivery & development
- Nanotechnology for drug and gene delivery
- Supercritical fluid technology for drug delivery systems
- Microfluidic technologies for drug delivery systems
- Antiangiogenic and anti-inflammatory drugs for the therapy of diabetic retinopathy, age related macular degeneration, and cancers
- Novel therapeutics for neonatal encephalopathy and epilepsy
2011-present Editor-in-Chief, Expert Opinion on Drug Delivery
2020-present Editor-in-Chief, Journal of Ocular Pharmacology and Therapeutics
2011-2020 Associate Editor (Drug Delivery), Journal of Ocular Pharmacology and Therapeutics
2008-2020 Field Editor, Research manuscripts, Pharmaceutical Research
2004-2008 Editor, Expert Reviews, Pharmaceutical Research
2004-12/2008 Editor, Clinical Research and Regulatory Affairs
Equipment available for experimental use in the Kompella lab includes:
- Tonopen Applanation Tonometer: 532 nm diode laser
- Ophthalmoscope and Slit Lamp
- Probe Sonicator with controllable power input
- Supercritical Fluid Apparatus: custom assembled
- Waters HPLC system: autoinjector, two pumps, a photodiode array detector, a fluorescence detector, and a controller
- LC/MS/MS system with an Agilent LC unit
- Buchi rotavapor R-200
- 12 Ussing chambers
- MaxQ 4000 Metabolic Shaker Incubator
- programmable incubation from 0 to 60 °C
- hacking speed ranging from 0-400 rpm
- Dual voltage-clamp unit
- Strip-chart recorder
- Temperature-controlled shaking water bath
- Temperature-controlled incubators (2)
- N-evap unit
- Digital Analytical Balance
- Laminar flow hoods (3)
- Humidified CO2 incubators (2)
- Leica microscope
- Spectramax M5 multi-detection plate reader with triple-mode cuvette port
- Zetasizer Nano
- Fluorotron Master